5 Results for "

PPAR agonist5

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "PPAR agonist5" in MCE Product Catalog:

  • Targets Recommended:
Cat. No.: HY-163547
CAS No.: 3059387-62-8
Target:  

PPAR

Research Areas:  

Inflammation/Immunology

PPAR agonist 5 (compound 4b) is a potent PPAR agonist with EC50 values of 3.20, 1.51, 1.92 µM for PPARα, PPARβ/δ, PPARγ, respectively. PPAR agonist 5 shows anti-inflammatory effect .
loading...
    loading...
Cat. No.: HY-146480
CAS No.: 915124-86-6
Purity:  98.59%
Target:  

PPAR

Research Areas:  

Cancer

PPARγ agonist 5 (Compound 1) is a potent and selective agonist of PPARγ. PPARγ agonist 5 has the potential for the research of cancer diseases .
loading...
    loading...
Cat. No.: HY-173217
Target:  

PPAR Phosphatase

PPARα agonist 5 is an orally available, selective partial agonist of PPARα (EC50: 3 nM). PPARα agonist 5 reduces lipid accumulation and upregulates key PPARα target genes, exerting anti-fatty liver effects. PPARα agonist 5 also exhibits significant hypolipidemic and hypoglycemic effects through partial PPARγ agonist activity and mild inhibition of protein tyrosine phosphatase 1B (PTP1B) (IC50: 79.1 μM). PPARα agonist 5 has a good safety profile and can be used in the study of type 2 diabetes with dyslipidemia .
loading...
    loading...
Cat. No.: HY-141494
Target:  

PPAR

Research Areas:  

Metabolic Disease

Pparδ agonist 5, an orally active PPARδ-selective agonist (EC50=0.335 μM), is much greater than that of the prototypical standard GW0742. Pparδ agonist 5 promotes improvements in bone density and microarchitecture in vivo .
loading...
    loading...
Cat. No.: HY-167950
CAS No.: 849150-59-0
Target:  

PPAR

Research Areas:  

Metabolic Disease

PPARα/γ agonist 5 is a dual PPARα/γ agonist with significant biological activity exhibited at low concentrations. The EC50 of PPARα/γ agonist 5 are 0.358μM and 1.21μM respectively, showing its potential in inhibiting type 2 diabetes and lipid metabolism disorders. PPARα/γ agonist 5 was selected for clinical development due to its high efficacy .
loading...
    loading...